drugset / Trial / NCT02736617
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
Phase 2
Completed
10 enrolled
OHSU Knight Cancer Institute
Genentech, Inc. · collabOregon Health and Science University · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well obinutuzumab works in combination with ibrutinib in treating patients with mantle cell lymphoma that has returned (relapsed) or that does not respond to treatment (refractory). Obinutuzumab binds to a protein called cluster of differentiation (CD)20, which is found on B cells and some types of leukemia and lymphoma cells and help the immune system kill cancer cells. Ibrutinib blocks a protein called Bruton's tyrosine kinase (BTK), which may help keep cancer cells from growing. Giving obinutuzumab in combination with ibrutinib may kill more cancer cells.
Timeline
- Start
- 2016-07-05
- Primary completion
- 2021-06-02
- Completion
- 2021-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | — | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | — | Intravenous |